Gelonghui, May 11丨Health Yuan (600380.SH) said at the performance briefing that the multi-center phase III clinical trial of TG-1000 capsules for uncomplicated acute influenza A and B infections aged 12 and above has now reached the main research end. The company will communicate with the Drug Evaluation Center (CDE) of the China Drug Administration about the marketing application of TG-1000 capsules to treat influenza in the near future to advance the marketing process of TG-1000 capsules. If there are any relevant developments in the future, the company will promptly disclose them as required.
健康元(600380.SH)：近期就TG-1000胶囊治疗流感的上市申请向国家药品监督管理局药品审评中心进行沟通
Health Source (600380.SH): Recently communicated with the Drug Evaluation Center of the State Drug Administration regarding the marketing application of TG-1000 capsules to treat influenza
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.